NasdaqCM:CORTPharmaceuticals
Lifyorli Survival Data and DOJ Update Might Change The Case For Investing In Corcept Therapeutics (CORT)
In late May and early June 2026, Corcept Therapeutics reported strong overall survival data for newly approved ovarian cancer drug Lifyorli from its Phase 3 ROSELLA trial at ASCO, while also disclosing that the U.S. Department of Justice declined to intervene in a long-running qui tam lawsuit related to Korlym’s promotion and reimbursement.
Beyond reinforcing Lifyorli’s clinical profile and guideline inclusion, these updates highlight Corcept’s evolution from a single-product Cushing’s...